ARCHIVES

Lilly Suspends Phase III Trial Of Tasisulam in Melanoma

This article is from The Cancer Letter archive.

Vol. 34 No. 1 | January 28, 2011

Download PDF Visit The Full Archive

Related Articles

Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial

October 26, 2012

In a letter, ASCO reaffirms its views on oncology consolidation at FDA.

July 9, 2004

Recommendation By Patients; report Of Protocol Committee

August 9, 1996

Creating the Modern Cancer Center

November 2, 2021

1985 International Cancer Congress to Be In Budapest

September 24, 1982

Clinical Trials Approved By NCI During November Are Listed

December 27, 2002